Improvement of Signs and Symptoms of Nonradiographic Axial Spondyloarthritis in Patients Treated With Secukinumab: Primary Results of a Randomized, Placebo‐Controlled Phase III Study

RCT (n=555) found 52 weeks of treatment with secukinumab 150mg every 4 weeks was superior to placebo for 40% improvement in disease activity according to Assessment of Spondyloarthritis International Society criteria (39.8% vs 19.9% p<0.05). No new safety findings were reported.

Source:

Arthritis & Rheumatology